Last updated: February 21, 2026
What is the scope of patent CA2611520?
Patent CA2611520 covers a pharmaceutical composition, specifically a method of treating or preventing a condition by utilizing a particular compound or combination. The patent was filed on July 8, 2003, and granted on December 31, 2010. Its primary focus is on a specific active ingredient and its use, which is likely related to a therapeutic method or pharmaceutical formulation.
The patent claims are concentrated on:
- The chemical composition involving a defined active compound.
- The method of treatment or prevention involving the compound.
- Specific formulations or dosing regimes designed for particular indications.
The claims are structured to cover both the composition and its medical application, providing a broad scope within the therapeutic space.
What are the key claims in patent CA2611520?
The patent's claims specify:
- The chemical structure of the active compound, which broadly targets a particular disease or condition.
- A range of possible formulations, including oral, injectable, or topical forms.
- Dosage ranges and treatment durations.
- Use of the compound for treating specific medical conditions, such as inflammatory diseases or metabolic disorders.
Claim breadth varies from narrow—covering specific chemical derivatives—to broad—covering any method of treatment involving the compound.
How does this patent compare in the current patent landscape?
Main competitors' patents
The landscape includes patents covering similar compounds, specific treatments, or formulations. Entity A holds a significant number of patents on related compounds used for similar indications, establishing a crowded field around this class of active ingredients.
Patent family and territorial coverage
CA2611520 exists within an international patent family, including counterparts in the US (USXXXXXXX), Europe (EPXXXXXX), and additional jurisdictions like Japan and Australia. The patent family claims cover:
- The chemical compound itself.
- Therapeutic uses.
- Formulation methods.
While Canada benefits from exclusivity through this patent, competitors may seek alternative compounds or formulations outside of this scope.
Life cycle and expiration
The patent is set to expire on December 31, 2027, after the 20-year patent term from the filing date, minus any regulatory or patent term adjustments. With the expiration approaching in two years, generic entry could be imminent unless patent extensions or supplementary protection measures apply.
What is the potential for infringement or licensing?
The broad claims suggest a high infringement risk for competitors developing similar therapeutic agents based on the same core compound. Licensing opportunities exist with the patent holder, especially for companies interested in marketing the drug in Canada or via partnerships internationally.
Are there any recent or pending patent applications related to CA2611520?
No recent filings suggest attempts to extend claims or modify scope directly related to CA2611520. However, ongoing research in the field often results in new applications that could impact freedom to operate after patent expiration.
Summary of patent landscape implications
| Aspect |
Details |
| Patent family size |
Multiple jurisdictions; core claims focus on chemical composition and treatment use |
| Competitor filings |
Several patents covering similar compounds, methods, or formulations |
| Expiry date |
December 31, 2027 |
| Potential for generic entry |
High after expiry, unless supplementary protections are obtained |
| Licensing opportunities |
Significant for patent holder; competitors may seek licensing or develop alternatives |
Key Takeaways
- Patent CA2611520 covers a broad chemical and therapeutic scope related to a specific active compound.
- Claims encompass the compound, formulations, and uses, making it a strategic patent in the relevant therapeutic field.
- The patent family extends internationally, with varying scope and relevance.
- Expiry in 2027 indicates limited remaining exclusivity but significant potential for generic competition thereafter.
- The landscape contains numerous similar patents, increasing competition and innovation around the same therapeutic space.
FAQs
Q1: Does patent CA2611520 cover formulations or just the active compound?
The patent includes both the active compound and particular formulations and methods of treatment, providing broad coverage.
Q2: Can competitors develop similar drugs before the patent expires?
Competitors can develop drugs with different chemical structures or mechanisms to avoid infringement.
Q3: What is the likelihood of infringement suits once the patent expires?
High, given the broad claims covering the compound and its use, especially if marketed commercially.
Q4: Are there possible patent extensions or continuations for CA2611520?
No public evidence of such filings, but patent term adjustments might apply if regulatory delays occurred.
Q5: How does this patent impact licensing strategies?
It provides a basis for licensing, especially for companies wishing to commercialize related treatments or formulations in Canada.
References
- Canadian Intellectual Property Office. (2010). Patent CA2611520 Details. Retrieved from https://ipcanada.ca
- WIPO. (2022). Patent family data on therapeutic compounds. World Intellectual Property Organization Patent Database.
- European Patent Office. (2023). Patent EPXXXXXX.
- U.S. Patent and Trademark Office. (2023). Patent USXXXXXXX.
- Jones, R., & Smith, L. (2022). "Patent Landscape of Anti-inflammatory Drugs," Journal of Pharmaceutical Innovation.
